Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein for patients with chronic hepatitis B and C: a comparative study

We compared Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein (WFA+‐M2BP) levels between patients with chronic hepatitis B (n=249) and chronic hepatitis C (n=386) based on the degree of liver fibrosis. We examined WFA+‐M2BP levels in patients with F4 (cirrhosis), F3 or more (advanced fibrosis) and F2 or more (significant fibrosis) in the two groups. We further examined the relationship between five fibrosis markers and the degree of fibrosis. The WFA+‐M2BP values ranged from 0.25 cut‐off index (COI) to 12.9 COI in patients with hepatitis B and 0.34–20.0 COI in patients with hepatitis C (P<.0001). The median WFA+‐M2BP values in F4 in the two groups were 2.83 COI in patients with hepatitis B and 5.03 COI in patients with hepatitis C (P=.0046). The median WFA+‐M2BP values in F3 or more in the two groups were 1.79 COI in patients with hepatitis B and 3.79 COI in patients with hepatitis C (P<.0001). The median WFA+‐M2BP values in F2 or more in the two groups were 1.49 COI in the hepatitis B cohort and 3.19 COI in the hepatitis C group (P<.0001). Among five liver fibrosis markers, WFA+‐M2BP had the highest correlation coefficient (rs=.629) in terms of correlation with the degree of fibrosis in the patients with hepatitis C and had the second highest rs value (.415) in the hepatitis B group. Although WFA+‐M2BP could be a useful indicator of liver fibrosis, WFA+‐M2BP levels in the two groups significantly differed even in the same degree of fibrosis. Individual cut‐off values in each aetiology for the degree of fibrosis should be determined.

[1]  R. Takata,et al.  Clinical implications of serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein in treatment‐naïve chronic hepatitis B , 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  R. Takata,et al.  Clinical significance of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein level in non‐alcoholic steatohepatitis , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  R. Takata,et al.  Clinical implication of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein level on hepatitis B e‐antigen loss or seroconversion in hepatitis B e‐antigen positive patients , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  R. Takata,et al.  Clinical significance of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein level and high‐sensitivity C‐reactive protein concentration in autoimmune hepatitis , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[5]  R. Takata,et al.  Impact of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein and serum interferon‐γ‐inducible protein‐10 in primary biliary cirrhosis , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  Rohit Loomba,et al.  Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. , 2016, Journal of hepatology.

[7]  M. Mizokami,et al.  Serum WFA+‐M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[8]  H. Janssen,et al.  New therapeutic agents for chronic hepatitis B. , 2016, The Lancet. Infectious diseases.

[9]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[10]  J. Hayashi,et al.  Serum WFA+‐M2BP is a non‐invasive liver fibrosis marker that can predict the efficacy of direct‐acting anti‐viral‐based triple therapy for chronic hepatitis C , 2016, Alimentary pharmacology & therapeutics.

[11]  M. Shimizu,et al.  Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac‐2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  M. Kurosaki,et al.  Wisteria floribunda agglutinin positive human Mac‐2‐binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[13]  M. Ota,et al.  Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis , 2015, The American Journal of Gastroenterology.

[14]  P. Klenerman,et al.  Hepatitis C , 2015, The Lancet.

[15]  A. Kuno,et al.  Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma , 2015, Journal of Gastroenterology.

[16]  R. Thimme,et al.  Natural history of chronic hepatitis B virus infection , 2015, Medical Microbiology and Immunology.

[17]  P. Bedossa.  Reversibility of hepatitis B virus cirrhosis after therapy: who and why? , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[18]  Lunan Yan,et al.  Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta‐analysis , 2015, Hepatology.

[19]  A. Tamori,et al.  Clinical significance of pretreatment serum interferon‐gamma‐inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir‐based triple therapy , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[20]  G. Dusheiko,et al.  Natural history of hepatitis C. , 2014, Journal of hepatology.

[21]  A. Kuno,et al.  Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients , 2014, Hepatology.

[22]  G. Wong,et al.  Prediction of fibrosis progression in chronic viral hepatitis , 2014, Clinical and molecular hepatology.

[23]  H. Parsian,et al.  Hyaluronic Acid: From Biochemical Characteristics to its Clinical Translation in Assessment of Liver Fibrosis , 2013, Hepatitis monthly.

[24]  H. Rosen.  Clinical practice. Chronic hepatitis C infection. , 2011, The New England journal of medicine.

[25]  Ying Sun,et al.  Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.

[26]  Y. Paik,et al.  Validation of FIB‐4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus‐infected patients , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[27]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[28]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[29]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[30]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[31]  L. Seeff,et al.  Natural history of hepatitis C , 1997, Hepatology.

[32]  P. Gibson,et al.  Effects of eating on plasma hyaluronan in patients with cirrhosis: Its mechanism and influence on clinical interpretation , 1998, Journal of gastroenterology and hepatology.

[33]  Chien-Jen Chen,et al.  Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.

[34]  M. Kojiro,et al.  Long‐term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: Morphometric analysis of repeated biopsies , 1997, Hepatology.

[35]  M. Kojiro,et al.  Pathomorphological study of HCV antibody‐positive liver cirrhosis , 1994, Journal of gastroenterology and hepatology.

[36]  P. Bedossa,et al.  Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .

[37]  E. Schiff,et al.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. , 1993, Gastroenterology.

[38]  Y. Maehara,et al.  A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis , 2014, Journal of Gastroenterology.

[39]  박준용,et al.  Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients , 2010 .

[40]  Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. , 1994, Hepatology.

[41]  R. W. Mccollum.  The natural history of hepatitis. , 1969, Bulletin of the New York Academy of Medicine.